Company intelligence / Profile preview

Neuorna Therapeutics

Watertown, Massachusetts, United Statesneuronatherapeutics.com ↗

Ownership: Private
Employees: ~110
Development stage: Phase 1

Overview

Currently conducting Phase 3 clinical trials for navacaprant (NMRA-140) for major depressive disorder and Phase 1 trials for NMRA-511 for agitation associated with dementia due to Alzheimer's disease

Therapeutic areas: PsychiatryNeurology
Modalities: Small molecules
Industry: Biotech

Drug pipeline

1 asset

NRTX-1001

Phase 1/2

Indications: Epilepsy

Beyond the preview

Go deeper on Neuorna Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Neuorna Therapeutics.

Explore the full profile